Cabometyx
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple tyrosine kinases including MET, AXL, and vascular endothelial growth factor receptor (VEGFR). VEGF production is upregulated in renal cell carcinoma and results in increased tumor vascularization and disease progression. Standard first-line therapies such as Sutent (sunitinib; Pfizer) work by targeting VEGF/VEGFR signaling; however, tumors often develop resistance to these anti-angiogenic treatments. Aberrant expression of MET and AXL tyrosine kinases is associated with drug resistance and poor disease prognosis; by targeting MET and AXL, as well as VEGF/VEGFR signaling, Cabometyx may provide an alternative treatment option for patients in the relapsed setting.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Cabometyx : Hepatocellular carcinoma (HCC)
15 Cabometyx : Renal cell carcinoma (RCC)
LIST OF FIGURES
10 Figure 1: Datamonitor Healthcare’s drug assessment summary of Cabometyx for HCC
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Cabometyx for HCC
13 Figure 3: Cabometyx sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
21 Figure 4: Cabometyx for RCC – SWOT analysis
22 Figure 5: Datamonitor Healthcare’s drug assessment summary of Cabometyx for RCC
23 Figure 6: Datamonitor Healthcare’s drug assessment summary of Cabometyx for RCC
25 Figure 7: Cabometyx sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Recent high-impact events for Cabometyx in HCC
6 Table 2: Cabometyx drug profile
7 Table 3: Approval history of Cabometyx for HCC in the US, Japan, and five major EU markets
8 Table 4: Trials of Cabometyx for HCC
9 Table 5: Cabometyx for HCC – SWOT analysis
16 Table 6: Cabometyx drug profile
17 Table 7: Cabometyx Phase III data in RCC
20 Table 8: Cabometyx’s ongoing trials in RCC
26 Table 9: Cabometyx sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
In Vivo’s Quick Guide To Gene Therapy 
Sign up to the